Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Policy Says Right-to-Try Talks Are Between Providers, Sponsors

Aug 17 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate

Aug 03 2017

Expanded Access: FDA To Clarify How Adverse Events Impact Drug Approval Process

Jul 21 2017

User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

Jul 13 2017

Chimerix And FDA’s Compassionate-Use Solution

Mar 26 2014

J&J's Compassionate Use Advisory Cmte. May Become Industry Model

May 09 2016

FDA Makes Expanded Access Applications Easier As Industry Lawyers Urge Caution

Feb 04 2015

'Right To Try' Or 'Right To Ask'? Hearing Spotlights Adverse Events As Key Barrier To Expanded Access

Sep 26 2016

FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide

Jun 06 2016

Related Companies

Chimerix, Inc.

Johnson & Johnson

Additional Topics

United States FDA Research & Development Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window